Arthritis (or osteoarthritis) of joints affects to some extent every other person over the age of 50 and thus ranks among one of the most common diseases in general.

The patient base for arthritis and therefore its patient market size is large.

Severe arthritis that requires medical intervention affects approximately
30 million people
in the European Union.

This company already has treated thousands of patients, but will need to get permission from the European medical boards to market this same procedure in various European markets.

The company has presented and published many reports based on its own experience from non-randomized case-control study of over 1000 patients that demonstrated safety and clinical effect in 63-91% of patients with osteoarthritis of the knee and hip.

The major limitation of this study was the lesser level of confidentiality according to evidence-based medicine standards. Therefore the company needs to perform a new original double-blind, randomized, placebo-controlled clinical study that represents the highest possible level of evidence-based medicine that cellular therapy based on freshly isolated SVF (Stromal vascular fraction) cells from adipose and connective tissue is safe and has a beneficial effect on arthritis of the joints, especially knees and hips, which are most frequently affected.

  • The clinical trials will enable the company to request approvals from the EMA and the various European countries for commercialization of its Stem Cell treatments for orthopedics.

  • Upon approval, it will enable the Company to bring its patented and highly effective Stem Cell technology to market to treat orthopedic patients with hip and knee joint problems with regenerative Stem Cell therapy as opposed to traditional and costly hip and knee replacements

  • With the right approvals and licenses in place, the company will generate high margin profits from its Stem Cell treatments to treat osteoarthritis patients with innovative regenerative technology

  • It is the newest innovation with a proven track record that over time may replace artificial hip and knee implants in all of Europe